Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC). It is designed to identify and merge with a private company. Now — the numbers.
There is not enough trading history here to call this an established business.
If every debt were paid off today, $1.4M would still be left — though next to the size of the company that is a thin cushion.
The market pays 34.3× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
There is $1.4M in the vault; even if every debt were paid off, $1.4M would remain.
The stock sits at $0.89. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown.